Subscription
Last updated on 23-Jun-2025 19:09:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 712000 | 238400 | 0.33 |
| NIB | 604400 | 423600 | 0.7 |
| RETAIL | 1248000 | 1118400 | 0.9 |
| Total | 2564400 | 1780400 | 0.69 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 1 |
| NIB | 49 |
| RETAIL | 699 |
| Total | 749 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 5.13 | 1.72 | 0.33 |
| FII | - | 1.72 | - |
| FI | - | 0 | - |
| IC | - | 0 | - |
| MF | - | 0 | - |
| OTH | - | 0 | - |
| NIB | 4.35 | 3.05 | 0.7 |
| RETAIL | 8.99 | 8.05 | 0.9 |
| Total | 18.46 | 12.82 | 0.69 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0 | @8% ₹0 | @9% ₹0 | @10% ₹0 | @11% ₹0.1 | @12% ₹0.1 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.1 | @8% ₹0.1 | @9% ₹0.1 | @10% ₹0.1 | @11% ₹0.1 | @12% ₹0.1 |
About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail (10000 to 2 lakh) | 1 | 1600 | 115200 | 780 |
| HNI (2 lakh to 5 lakh) | 2 | 3200 | 230400 | 378 |
Aakaar Medical Technologies IPO Details
| Issue Size | 37,50,400 shares (aggregating up to ₹27.00 Cr) |
| Fresh Issue | 37,50,400 shares (aggregating up to ₹27.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,04,22,416 shares |
| Share Holding Post Issue | 1,41,72,816 shares |
| Market Maker Portion | 1,88,800 shares Alacrity Securities Ltd. |
Aakaar Medical Technologies IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Isssue |
Key Performance Indicator (KPI)
| KPI | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROCE | 21.02% | 17.68% | 22.30% |
| D/E | 0.98 | 1.2 | 0.61 |
| RONW | 33.81% | 25.88% | 24.35% |
| EPS (basic) | 6.13 | 3.14 | 2.36 |
| P/E Pre IPO | 12.43 | ||
| P/E Post IPO | 16.9 |
Company Financials In Crores
| Period Ended | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| Assets | 51.9 | 34.0 | 23.2 |
| Revenue | 61.8 | 46.3 | 32.9 |
| Profit After Tax | 6.0 | 2.9 | 2.2 |
| Net Worth | 23.2 | 12.5 | 9.7 |
| Reserves and Surplus | 12.8 | 11.8 | 9.0 |
| Total Borrowing | 22.7 | 15.1 | 5.9 |
About Company
Incorporation: June 2013
Business: Aesthetic medical company specializing in cosmetic products and devices for dermatologists, plastic surgeons, and aesthetic physicians.
Target Clients: Dermatologists | Plastic Surgeons | Aesthetic Physicians | Cosmetologists
Key Business Highlights
Product Portfolio:
Domestically manufactured products.
Internationally produced devices (imported).
Imported Brands: Sourced from South Korea, Spain, Italy, Austria.
Categories:
Skincare: Homecare & professional products.
Injectable & Contouring: Fillers, botox, etc.
Hair Care: Growth serums, anti-hair loss solutions, tablets.
Devices:
Laser hair reduction | Hair transplant devices
Tattoo removal | Skin rejuvenation | Urinary incontinence devices
Medifacial kits
Distribution Model:
B2B Focus: Supplies to clinics/hospitals (doctors resell to end-users or use in treatments).
Consignment Sales Partners: Enables Pan-India reach.
Geographic Presence:
15+ States: Delhi, Haryana, Punjab, Chandigarh, UP, Bihar, West Bengal, Assam, Gujarat, MP, Maharashtra, Karnataka, Telangana, Tamil Nadu.
Branches: Multiple across India.
Team: 90+ trained sales/service engineers → Ensures product support and customer satisfaction.
Strength
Experienced Leadership – Industry-savvy management with deep expertise in aesthetic medicine.
Comprehensive Product Portfolio – Diverse mix of devices and consumables across own and imported brands.
Wide Geographic Reach – Pan-India presence enabled by consignment partners and direct branches.
Weakness
Dependence on Imported Brands – Heavy reliance on third-party imported products exposes the business to supply chain disruptions and foreign market risks.
Contract Manufacturing Risks – Dependence on external manufacturers and loan licensing partners poses risks related to supply continuity, quality control, and compliance.
Cost Volatility – Fluctuations in raw material, utility, and transportation costs can impact profitability and overall financial stability.
Lead Manager(s)
Address
801, Heritage Plaza,
Telli Galli Cross Road
Andheri (East),
Mumbai, Maharashtra, 400069
Phone: +91 84528 44024
Email: companysecretary@aakaarmedical.in
Website: https://aakaarmedical.in/